Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Steam recall expanded

This article was originally published in The Tan Sheet

Executive Summary

Nutracoastal Trading expands the voluntary recall of Steam dietary supplements to include lot 90260 because it includes undeclared tadalafil, the active ingredient in the prescription erectile dysfunction drug Cialis. The Freeport, N.Y., company first recalled Steam July 28 after FDA found it included sulfoaildenafil, an anolog of sildenafil, the active ingredient in Viagra (1"The Tan Sheet" Aug. 3, 2009, In Brief)

You may also be interested in...



Double trouble for Nutracoastal

The Freeport, N.Y., company voluntarily recalls two products it markets nationwide as dietary supplements after FDA finds they contain active pharmaceutical ingredients. The Steam supplement was found to have sulfoaildenafil, an analog of the erectile dysfunction drug sildenafil, Nutracoastal Trading and FDA announced July 28. The S-DROL product was found to contain the undeclared steroid desoxymethyltestosterone. FDA said Nutracoastal's steroid-containing tablets are similar to those involved in the agency's warning to American Cellular Labs, but would not confirm whether Nutracoastal's products were linked to any adverse event reports (see story p. 8)

ESMO: Evidence Piles Up For AZ’s Tagrisso With ADAURA CNS Data

A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.

Small Firms Get Year Reprieve From Compliance With US FDA’s Supplement Facts Label Changes

FDA has heard from some manufacturers that additional time is needed to meet all of the requirements, “especially during the COVID-19 pandemic.” Prior to the pandemic, agency announced enforcement discretion during 2020 for compliance by firms with more than $10m in annual sales.

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel